Patents Assigned to Vertex Pharmaceuticals, Incorporated
  • Modulators of alpha-1 antitrypsin
    Patent number: 11623924
    Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: April 11, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Michael John Boyd, Diane M. Boucher, Michael Aaron Brodney, Veronique Damagnez, Lev Tyler Dewey Fanning, Mary Elizabeth Eccles, Robert Francis Fimognari, Jr., Kevin James Gagnon, Pedro M. Garcia Barrantes, Simon Giroux, Ronald Lee Grey, Jr., Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Joshua Kennedy Hussey, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Adam Looker, Brad D. Maxwell, John Patrick Maxwell, Ales Medek, Mettachit Navamal, Philippe Marcel Nuhant, Setu Roday, Stefanie Roeper, Rupa Sawant, Yi Shi, Rebecca Jane Swett, Qing Tang, Timothy Lewis Tapley, Stephen A. Thomson, Michael Waldo, Jinwang Xu, Kevin Michael Cottrell
  • Inhibitors of APOL1 and methods of using same
    Patent number: 11618746
    Abstract: The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: April 4, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jingrong Cao, Jon H. Come, Leslie A. Dakin, Francois Denis, Warren A. Dorsch, Anne Fortier, Martine Hamel, Elaine B. Krueger, Brian Ledford, Suganthini S. Nanthakumar, Olivier Nicolas, Camil Sayegh, Timothy J. Senter, Tiansheng Wang, Michael Brodney, Kan-Nian Hu, Peter Rose, Kevin Gagnon, Yi Shi, Muna Shrestha, Ales Medek, Faith Witkos
  • MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
    Publication number: 20230100634
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: March 30, 2021
    Publication date: March 30, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Sabina HADIDA RUAH, Peter Diederik Jan GROOTENHUIS, Fredrick F. VAN GOOR, Jinglan ZHOU, Brian Richard BEAR, Mark Thomas MILLER, Jason McCARTNEY, Mehdi Michel Djamel NUMA
  • Modified urokinase-type plasminogen activator polypeptides and methods of use
    Patent number: 11613744
    Abstract: Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: March 28, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Edwin L. Madison, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
  • DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS
    Publication number: 20230092449
    Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.
    Type: Application
    Filed: November 16, 2022
    Publication date: March 23, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: George Harb, Chunhui Xie
  • Carboxamides as modulators of sodium channels
    Patent number: 11603351
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: March 14, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Nadia M. Ahmad, Corey Anderson, Vijayalaksmi Arumugam, Iuliana Luci Asgian, Joanne Louise Camp, Lev Tyler Dewey Fanning, Sara Sabina Hadida Ruah, Dennis Hurley, Yvonne Schmidt, David Shaw, Urvi Patel, Stephen Andrew Thomson, Lidio Marx Carvalho Meireles
  • Modulators of cystic fibrosis transmembrane conductance regulator
    Patent number: 11591350
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: February 28, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Process of making CFTR modulators
    Patent number: 11584761
    Abstract: The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: February 21, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Angell, John E. Cochran, Benjamin J. Littler, David Siesel, Armando Urbina, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
    Patent number: 11578062
    Abstract: The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: February 14, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ali Keshavarz-Shokri, Beili Zhang, Tim Edward Alcacio, Elaine Chungmin Lee, Yuegang Zhang, Mariusz Krawiec
  • Pteridinone compounds and uses thereof
    Patent number: 11572364
    Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: February 7, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Lauffer, Guy Bemis, Michael Boyd, David Deininger, Hongbo Deng, Warren Dorsch, Wenxin Gu, Russell R. Hoover, Mac Arthur Johnson, Jr., Mark Willem Ledeboer, Brian Ledford, Francois Maltais, Marina Penney, Darin Takemoto, Nathan D. Waal, Tiansheng Wang, Pan Li
  • Pharmaceutical composition and administrations thereof
    Patent number: 11564916
    Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: January 31, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D. J. Grootenhuis, Martyn Botfield, Alfredo Grossi
  • Materials and methods for treatment of hemoglobinopathies
    Patent number: 11566236
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for creating permanent changes to the genome that can result in at least one deletion, insertion, modulation, or inactivation of a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: January 31, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Tirtha Chakraborty, Michelle I-Ching Lin
  • Method of treating pain
    Patent number: 11529337
    Abstract: Provided is a method of treating or lessening the severity of pain in a subject, comprising administering to the subject a compound of formula (I), defined as described herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: December 20, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sagar Agarwal, Cynthia Barber, Francoise Berlioz-Seux, Brenda Cirincione, James Jones, Sandra Lechner, Marco Rizzo, David Stiles
  • Stem cell derived islet differentiation
    Patent number: 11525120
    Abstract: Provided herein are methods of producing ? cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: December 13, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Felicia J. Pagliuca, George Harb, Lillian Ye
  • Methods of treatment for cystic fibrosis
    Patent number: 11517564
    Abstract: Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: December 6, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Weichao George Chen, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz
  • FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
    Publication number: 20220354797
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a disintegrant, a surfactant, a binder, and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Processes of preparing pharmaceutical compositions comprising Compound 1 are also disclosed.
    Type: Application
    Filed: February 12, 2021
    Publication date: November 10, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventor: Marinus Jacobus Verwijs
  • Compounds useful as inhibitors of ATR kinase
    Patent number: 11485739
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: November 1, 2022
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
  • DEVICES AND METHODS FOR DELIVERING THERAPEUTICS
    Publication number: 20220331234
    Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.
    Type: Application
    Filed: May 4, 2022
    Publication date: October 20, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Yang Qiu
  • Devices and methods for delivering therapeutics
    Patent number: 11471398
    Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: October 18, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Yang Qui
  • Processes for making modulators of cystic fibrosis transmembrane conductance regulator
    Patent number: 11465985
    Abstract: The disclosure provides processes for preparing a compound of Formula (I).
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: October 11, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul T. Angell, Cristian Harrison, Robert M. Hughes, Berenice Lewandowski, Benjamin J. Littler, Vito Melillo, William A. Nugent, David Andrew Siesel, David Smith, John Studley